XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint

Principe, Daniel R.; Xiong, Rui; Li, Yangfeng; Pham, Thao N.D.; Kamath, Suneel D.; Dubrovskyi, Oleksii; Ratia, Kiira; Huang, Fei; Zhao, Jiong; Shen, Zhengnan; Thummuri, Dinesh; Daohong, Zhou; Underwood, Patrick W.; Trevino, Jose; Munshi, Hidayatullah G.; Thatcher, Gregory R.J.; Rana, Ajay

doi:10.1073/pnas.2116764119

Title: XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint

Journal Article · 01 January 2022 · Proc. Natl. Acad. Sci. USA

DOI:https://doi.org/10.1073/pnas.2116764119· OSTI ID:1863043

Principe, Daniel R.; Xiong, Rui; Li, Yangfeng; Pham, Thao N.D.; Kamath, Suneel D.; Dubrovskyi, Oleksii; Ratia, Kiira; Huang, Fei; Zhao, Jiong; Shen, Zhengnan; Thummuri, Dinesh; Daohong, Zhou; Underwood, Patrick W.; Trevino, Jose; Munshi, Hidayatullah G.; Thatcher, Gregory R.J.; Rana, Ajay

Cite

Export

Save

Research Organization:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Organization:: DOE - Office Of Science; OTHER U.S. GOVERNMENT

OSTI ID:: 1863043

Journal Information:: Proc. Natl. Acad. Sci. USA, Vol. 119, Issue (4)

Country of Publication:: United States

Language:: ENGLISH

References (71)

Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Hessmann, Elisabeth; Johnsen, Steven A.; Siveke, Jens T. Gut, Vol. 66, Issue 1 https://doi.org/10.1136/gutjnl-2016-312539	journal	November 2016
BET Proteins as Targets for Anticancer Treatment Stathis, Anastasios; Bertoni, Francesco Cancer Discovery, Vol. 8, Issue 1 https://doi.org/10.1158/2159-8290.CD-17-0605	journal	December 2017
Targeting BET bromodomain proteins in solid tumors Sahai, Vaibhav; Redig, Amanda J.; Collier, Katharine A. Oncotarget, Vol. 7, Issue 33 https://doi.org/10.18632/oncotarget.9804	journal	June 2016
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma Mazur, Pawel K.; Herner, Alexander; Mello, Stephano S. Nature Medicine, Vol. 21, Issue 10 https://doi.org/10.1038/nm.3952	journal	September 2015
BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen Sahai, Vaibhav; Kumar, Krishan; Knab, Lawrence M. Molecular Cancer Therapeutics, Vol. 13, Issue 7 https://doi.org/10.1158/1535-7163.MCT-13-0925	journal	May 2014
Induction of MNK Kinase–dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors Pham, Thao N. D.; Kumar, Krishan; DeCant, Brian T. Molecular Cancer Therapeutics, Vol. 18, Issue 2 https://doi.org/10.1158/1535-7163.MCT-18-0768	journal	November 2018
BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo Kumar, Krishan; DeCant, Brian T.; Grippo, Paul J. JCI Insight, Vol. 2, Issue 3 https://doi.org/10.1172/jci.insight.88032	journal	February 2017
Bromodomain: an acetyl-lysine binding domain Zeng, Lei; Zhou, Ming-Ming FEBS Letters, Vol. 513, Issue 1 https://doi.org/10.1016/S0014-5793(01)03309-9	journal	January 2002
BET domain co-regulators in obesity, inflammation and cancer Belkina, Anna C.; Denis, Gerald V. Nature Reviews Cancer, Vol. 12, Issue 7 https://doi.org/10.1038/nrc3256	journal	June 2012
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc Delmore, Jake E.; Issa, Ghayas C.; Lemieux, Madeleine E. Cell, Vol. 146, Issue 6 https://doi.org/10.1016/j.cell.2011.08.017	journal	September 2011
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers Lovén, Jakob; Hoke, Heather A.; Lin, Charles Y. Cell, Vol. 153, Issue 2 https://doi.org/10.1016/j.cell.2013.03.036	journal	April 2013
Selective inhibition of BET bromodomains Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah Nature, Vol. 468, Issue 7327 https://doi.org/10.1038/nature09504	journal	September 2010
Targeting chromatin remodelling proteins to treat pancreatic cancer Thomas, Hugh Nature Reviews Gastroenterology & Hepatology, Vol. 12, Issue 11 https://doi.org/10.1038/nrgastro.2015.171	journal	October 2015
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition Shi, Junwei; Vakoc, Christopher R. Molecular Cell, Vol. 54, Issue 5 https://doi.org/10.1016/j.molcel.2014.05.016	journal	June 2014
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy Manzotti, Gloria; Ciarrocchi, Alessia; Sancisi, Valentina Cancers, Vol. 11, Issue 3 https://doi.org/10.3390/cancers11030304	journal	March 2019
Structure and ligand of a histone acetyltransferase bromodomain Dhalluin, Christophe; Carlson, Justin E.; Zeng, Lei Nature, Vol. 399, Issue 6735 https://doi.org/10.1038/20974	journal	June 1999
Bromodomain and Histone Acetyltransferase Domain Specificities Control Mixed Lineage Leukemia Phenotype Santillan, Donna A.; Theisler, Catherine M.; Ryan, Amanda S. Cancer Research, Vol. 66, Issue 20 https://doi.org/10.1158/0008-5472.CAN-06-2597	journal	October 2006
Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains Hay, Duncan A.; Fedorov, Oleg; Martin, Sarah Journal of the American Chemical Society, Vol. 136, Issue 26 https://doi.org/10.1021/ja412434f	journal	June 2014
CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation Garcia-Carpizo, Veronica; Ruiz-Llorente, Sergio; Sarmentero, Jacinto Epigenetics & Chromatin, Vol. 11, Issue 1 https://doi.org/10.1186/s13072-018-0197-x	journal	June 2018
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma Conery, Andrew R.; Centore, Richard C.; Neiss, Adrianne eLife, Vol. 5 https://doi.org/10.7554/eLife.10483	journal	January 2016
The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer Yan, Yuqian; Ma, Jian; Wang, Dejie EMBO Molecular Medicine, Vol. 11, Issue 11 https://doi.org/10.15252/emmm.201910659	journal	September 2019
Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma Zhang, Xin; Zegar, Tim; Lucas, Anais Oncogene, Vol. 39, Issue 24 https://doi.org/10.1038/s41388-020-1301-9	journal	May 2020
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib Li, Yangfeng; Zhao, Jiong; Gutgesell, Lauren M. Journal of Medicinal Chemistry, Vol. 63, Issue 13 https://doi.org/10.1021/acs.jmedchem.0c00456	journal	May 2020
TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer Principe, Daniel R.; Park, Alex; Dorman, Matthew J. Molecular Cancer Therapeutics, Vol. 18, Issue 3 https://doi.org/10.1158/1535-7163.MCT-18-0850	journal	December 2018
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy Principe, Daniel R.; Narbutis, Matthew; Kumar, Sandeep Cancer Research, Vol. 80, Issue 15 https://doi.org/10.1158/0008-5472.CAN-19-2959	journal	April 2020
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses Hammitzsch, Ariane; Tallant, Cynthia; Fedorov, Oleg Proceedings of the National Academy of Sciences, Vol. 112, Issue 34 https://doi.org/10.1073/pnas.1501956112	journal	August 2015
Cation–π interactions in CREBBP bromodomain inhibition: an electrostatic model for small-molecule binding affinity and selectivity Cortopassi, Wilian A.; Kumar, Kiran; Paton, Robert S. Organic & Biomolecular Chemistry, Vol. 14, Issue 46 https://doi.org/10.1039/C6OB02234K	journal	January 2016
Cation–π interactions in protein–ligand binding: theory and data-mining reveal different roles for lysine and arginine Kumar, Kiran; Woo, Shin M.; Siu, Thomas Chemical Science, Vol. 9, Issue 10 https://doi.org/10.1039/C7SC04905F	journal	January 2018
Organotypic slice cultures of pancreatic ductal adenocarcinoma preserve the tumor microenvironment and provide a platform for drug response Lim, Chae Yoon; Chang, Jae Hyuck; Lee, Won Sun Pancreatology, Vol. 18, Issue 8 https://doi.org/10.1016/j.pan.2018.09.009	journal	December 2018
Genetically Engineered Mouse Models of Pancreatic Cancer Westphalen, Christoph Benedikt; Olive, Kenneth P. The Cancer Journal, Vol. 18, Issue 6 https://doi.org/10.1097/PPO.0b013e31827ab4c4	journal	January 2012
Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models DeCant, Brian T.; Principe, Daniel R.; Guerra, Carmen Frontiers in Physiology, Vol. 5 https://doi.org/10.3389/fphys.2014.00464	journal	December 2014
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice Hingorani, Sunil R.; Wang, Lifu; Multani, Asha S. Cancer Cell, Vol. 7, Issue 5 https://doi.org/10.1016/j.ccr.2005.04.023	journal	May 2005
Cancer statistics, 2019 Siegel, Rebecca L.; Miller, Kimberly D.; Jemal, Ahmedin CA: A Cancer Journal for Clinicians, Vol. 69, Issue 1 https://doi.org/10.3322/caac.21551	journal	October 2018
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy Kunk, Paul R.; Bauer, Todd W.; Slingluff, Craig L. Journal for ImmunoTherapy of Cancer, Vol. 4, Issue 1 https://doi.org/10.1186/s40425-016-0119-z	journal	March 2016
Trials and tribulations of pancreatic cancer immunotherapy Principe, Daniel R.; Korc, Murray; Kamath, Suneel D. Cancer Letters, Vol. 504 https://doi.org/10.1016/j.canlet.2021.01.031	journal	April 2021
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine Xie, Fang; Huang, Mei; Lin, Xiansheng Scientific Reports, Vol. 8, Issue 1 https://doi.org/10.1038/s41598-018-26496-0	journal	May 2018
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors Miller, Aubrey L.; Fehling, Samuel C.; Garcia, Patrick L. EBioMedicine, Vol. 44 https://doi.org/10.1016/j.ebiom.2019.05.035	journal	June 2019
Brd4’s Bromodomains Mediate Histone H3 Acetylation and Chromatin Remodeling in Pluripotent Cells through P300 and Brg1 Wu, Tao; Kamikawa, Yasunao F.; Donohoe, Mary E. Cell Reports, Vol. 25, Issue 7 https://doi.org/10.1016/j.celrep.2018.10.003	journal	November 2018
C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer Ono, Hiroaki; Kato, Tomotaka; Murase, Yoshiki Scientific Reports, Vol. 11, Issue 1 https://doi.org/10.1038/s41598-021-89530-8	journal	May 2021
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer Buscail, Louis; Bournet, Barbara; Cordelier, Pierre Nature Reviews Gastroenterology & Hepatology, Vol. 17, Issue 3 https://doi.org/10.1038/s41575-019-0245-4	journal	January 2020
Roles for KRAS in Pancreatic Tumor Development and Progression di Magliano, Marina Pasca; Logsdon, Craig D. Gastroenterology, Vol. 144, Issue 6 https://doi.org/10.1053/j.gastro.2013.01.071	journal	May 2013
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas Smit, Vincent T. H. B. M.; Boot, Angelina J. M.; Smits, Alida M. M. Nucleic Acids Research, Vol. 16, Issue 16 https://doi.org/10.1093/nar/16.16.7773	journal	January 1988
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes Almoguera, Concepcion; Shibata, Darryl; Forrester, Kathleen Cell, Vol. 53, Issue 4 https://doi.org/10.1016/0092-8674(88)90571-5	journal	May 1988
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice Collins, Meredith A.; Bednar, Filip; Zhang, Yaqing Journal of Clinical Investigation, Vol. 122, Issue 2 https://doi.org/10.1172/JCI59227	journal	February 2012
Targeting the untargetable KRAS in cancer therapy Liu, Pingyu; Wang, Yijun; Li, Xin Acta Pharmaceutica Sinica B, Vol. 9, Issue 5 https://doi.org/10.1016/j.apsb.2019.03.002	journal	September 2019
CodeBreak 100: Phase I study of AMG 510, a novel KRAS ^G12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Hong, David S.; Kuo, James; Sacher, Adrian G. Journal of Clinical Oncology, Vol. 38, Issue 15_suppl https://doi.org/10.1200/JCO.2020.38.15_suppl.3511	journal	May 2020
Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer Shimamura, Takeshi; Chen, Zhao; Soucheray, Margaret Clinical Cancer Research, Vol. 19, Issue 22 https://doi.org/10.1158/1078-0432.CCR-12-3904	journal	September 2013
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors Piha-Paul, Sarina A.; Sachdev, Jasgit C.; Barve, Minal Clinical Cancer Research, Vol. 25, Issue 21 https://doi.org/10.1158/1078-0432.CCR-19-0578	journal	August 2019
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer Raina, Kanak; Lu, Jing; Qian, Yimin Proceedings of the National Academy of Sciences, Vol. 113, Issue 26 https://doi.org/10.1073/pnas.1521738113	journal	June 2016
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity Postel-Vinay, Sophie; Herbschleb, Karin; Massard, Christophe European Journal of Cancer, Vol. 109 https://doi.org/10.1016/j.ejca.2018.12.020	journal	March 2019
Functions of BET proteins in erythroid gene expression Stonestrom, Aaron J.; Hsu, Sarah C.; Jahn, Kristen S. Blood, Vol. 125, Issue 18 https://doi.org/10.1182/blood-2014-10-607309	journal	April 2015
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors Piha-Paul, Sarina A.; Hann, Christine L.; French, Christopher A. JNCI Cancer Spectrum, Vol. 4, Issue 2 https://doi.org/10.1093/jncics/pkz093	journal	November 2019
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors Lewin, Jeremy; Soria, Jean-Charles; Stathis, Anastasios Journal of Clinical Oncology, Vol. 36, Issue 30 https://doi.org/10.1200/JCO.2018.78.2292	journal	October 2018
Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease Nicholls, Stephen J.; Gordon, Allan; Johansson, Jan Journal of the American College of Cardiology, Vol. 57, Issue 9 https://doi.org/10.1016/j.jacc.2010.11.015	journal	March 2011
T-cell exhaustion in the tumor microenvironment Jiang, Y.; Li, Y.; Zhu, B. Cell Death & Disease, Vol. 6, Issue 6 https://doi.org/10.1038/cddis.2015.162	journal	June 2015
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Hodi, F. Stephen; O'Day, Steven J.; McDermott, David F. New England Journal of Medicine, Vol. 363, Issue 8 https://doi.org/10.1056/NEJMoa1003466	journal	August 2010
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Robert, Caroline; Thomas, Luc; Bondarenko, Igor New England Journal of Medicine, Vol. 364, Issue 26 https://doi.org/10.1056/NEJMoa1104621	journal	June 2011
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer Borghaei, Hossein; Paz-Ares, Luis; Horn, Leora New England Journal of Medicine, Vol. 373, Issue 17 https://doi.org/10.1056/NEJMoa1507643	journal	October 2015
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Garon, Edward B.; Rizvi, Naiyer A.; Hui, Rina New England Journal of Medicine, Vol. 372, Issue 21 https://doi.org/10.1056/NEJMoa1501824	journal	May 2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Larkin, James; Chiarion-Sileni, Vanna; Gonzalez, Rene New England Journal of Medicine, Vol. 373, Issue 1 https://doi.org/10.1056/NEJMoa1504030	journal	July 2015
Predictive biomarkers for checkpoint inhibitor-based immunotherapy Gibney, Geoffrey T.; Weiner, Louis M.; Atkins, Michael B. The Lancet Oncology, Vol. 17, Issue 12 https://doi.org/10.1016/S1470-2045(16)30406-5	journal	December 2016
Immune checkpoint inhibitors: recent progress and potential biomarkers Darvin, Pramod; Toor, Salman M.; Sasidharan Nair, Varun Experimental & Molecular Medicine, Vol. 50, Issue 12 https://doi.org/10.1038/s12276-018-0191-1	journal	December 2018
Immunotherapy for pancreatic cancer: Barriers and breakthroughs Torphy, Robert J.; Zhu, Yuwen; Schulick, Richard D. Annals of Gastroenterological Surgery, Vol. 2, Issue 4 https://doi.org/10.1002/ags3.12176	journal	June 2018
Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer Zhao, Jun; Wen, Xiaofei; Tian, Li Nature Communications, Vol. 10, Issue 1 https://doi.org/10.1038/s41467-019-08782-1	journal	February 2019
TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis Principe, Daniel R.; DeCant, Brian; Mascariñas, Emman Cancer Research, Vol. 76, Issue 9 https://doi.org/10.1158/0008-5472.CAN-15-1293	journal	March 2016
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression Zhu, Hengrui; Bengsch, Fee; Svoronos, Nikolaos Cell Reports, Vol. 16, Issue 11 https://doi.org/10.1016/j.celrep.2016.08.032	journal	September 2016
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 Hogg, Simon J.; Vervoort, Stephin J.; Deswal, Sumit Cell Reports, Vol. 18, Issue 9 https://doi.org/10.1016/j.celrep.2017.02.011	journal	February 2017
Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells Ebine, Kazumi; Kumar, Krishan; Pham, Thao N. Scientific Reports, Vol. 8, Issue 1 https://doi.org/10.1038/s41598-018-31658-1	journal	September 2018
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras -Mutant Non–Small Cell Lung Cancer Adeegbe, Dennis O.; Liu, Shengwu; Hattersley, Maureen M. Cancer Immunology Research, Vol. 6, Issue 10 https://doi.org/10.1158/2326-6066.CIR-18-0077	journal	August 2018
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1 Pan, Yu; Fei, Qinglin; Xiong, Ping OncoImmunology, Vol. 8, Issue 5 https://doi.org/10.1080/2162402X.2019.1581529	journal	March 2019
Immune Checkpoint Inhibitor Toxicities Marin-Acevedo, Julian A.; Chirila, Razvan M.; Dronca, Roxana S. Mayo Clinic Proceedings, Vol. 94, Issue 7 https://doi.org/10.1016/j.mayocp.2019.03.012	journal	July 2019

Similar Records

Melanoma Cell Intrinsic GABAA Receptor Enhancement Potentiates Radiation and Immune Checkpoint Inhibitor Response by Promoting Direct and T Cell-Mediated Antitumor Activity

Journal Article · 2021 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:1863043

Pomeranz Krummel, Daniel A.; Nasti, Tahseen H.; Kaluzova, Milota; +3 more

Revealing the mechanism of action of a first-in-class covalent inhibitor of $\mathrm{KRASG12C}$ $\mathrm{(ON)}$ and other functional properties of oncogenic $\text{KRAS}$ by ³¹P $\mathrm{NMR}$

Journal Article · 2024 · Journal of Biological Chemistry · OSTI ID:1863043

Sharma, Alok K.; Pei, Jun; Yang, Yue; +13 more

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy

Journal Article · 2017 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:1863043

Bang, Andrew; Wilhite, Tyler J.; Pike, Luke R.G.; +8 more

Title: XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint

Citation Formats

References (71)

Similar Records

Related Subjects